Meeting Minutes: Drug Formulary Committee - DRAFT

Date and Time: May 12, 2022; 5:15-9:00 p.m.
Minutes prepared by: Naana Osei-Boateng and Dave Hoang
Location: Virtual Meeting via Zoom

Attendance

- **Members in attendance:** Stuart Williams, JD; Kelly Ruby, PharmD; Monica Brands, RPh; Kathryn Lombardo, MD; Margaret Artz, RPh, PhD; Kathryn Montag-Shafer, PharmD; Ronda Chakolis, PharmD; James Phillips, MD; Mary Mescher Benbenek, APRN, PhD
- **Members absent:** Tim Cernohous, PharmD; Tsewang Ngodup, MD; Kyle Lehenbauer, MD; Michael Sprehe, MD
- **DHS staff present:** Dave Hoang, PharmD, MBA
- **Others in attendance:** Katie Counts, PharmD; Naana Osei-Boateng, PharmD

Report of the Chair

- Stuart Williams presided over the meeting and welcomed newly appointed member Ronda Chakolis, PharmD, and newly reappointed members James Phillips, MD; Mary Mescher Benbenek, APRN, PhD; and Margaret Artz, RPh, PhD

Approval of Minutes

- The committee reviewed and accepted the Minutes from the March 2022 meeting as presented.

DHS Housekeeping

- Dave Hoang outlined a contingency plan for the virtual meeting in case of weather disruptions during the meeting.

Old Business – None

New Business
Existing Specialty Drugs for Continued Prior Authorization (PA)

- The committee discussed the proposed updated Emflaza PA Criteria and recommended the policy to the Department of Human Services (DHS) by a unanimous vote with the following changes:
  - Amend 6th bullet point under Initial approval to read: Prescriber attests that multidisciplinary rehabilitation assessments are conducted every 6–12 months.
  - Amend 2nd bullet point under Renewal criteria to read: Prescriber attests that multidisciplinary rehabilitation assessments are conducted every 6–12 months.

Preferred Drug List (PDL) Review

Discussion Items:

- The committee discussed the Acne Agents, Topical therapeutic class and recommended the following to DHS by a unanimous vote:
  - BENZACLIN W/PUMP (TOPICAL) to be moved from NONPREFERRED to the PREFERRED PDL
  - AMZEEQ (TOPICAL), AVAR CLEANSER (TOPICAL), CLINDAMYCIN PHOSPHATE GEL (CLINDAGEL) (TOPICAL), DIFFERIN GEL OTC (TOPICAL), OVACE PLUS CREAM ER (TOPICAL), OVACE PLUS SHAMPOO (TOPICAL), SULFACETAMIDE/SULFUR SUSPENSION (TOPICAL) and WINLEVI (TOPICAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Analgesics, Narcotics Long therapeutic class and recommended the following to DHS by a unanimous vote:
  - BUPRENORPHINE (BUCCAL) to be added to the PDL as NONPREFERRED

- The committee discussed Angiotensin Modulator Combinations therapeutic class and recommended the following to DHS by a unanimous vote:
  - AMLODIPINE / VALSARTAN / HCTZ (ORAL) to be moved from PREFERRED to the NONPREFERRED PDL
  - BYVALSON (ORAL), TARKA (ORAL) and TWYNSTA (ORAL) to be removed from the PDL

- The committee discussed the Angiotensin Modulators therapeutic class and recommended the following to DHS by a unanimous vote:
  - ACEON (ORAL) to be removed from PDL
  - ENALAPRIL SOLUTION (ORAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Anticoagulants therapeutic class and recommended the following to DHS by a unanimous vote:
  - XARELTO SOLUTION (ORAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Anticonvulsants therapeutic class and recommended the following to DHS by a unanimous vote:
- LACOSAMIDE TABLET (ORAL) to be added to the PDL as PREFERRED
- ELEPSIA XR TABLET (ORAL) and RUFINAMIDE TABLET (ORAL) to be added to the PDL as NONPREFERRED
- DEPAKENE CAPSULE (ORAL) and DEPAKENE SYRUP (ORAL) to be removed from the PDL

- The committee discussed the Antidepressants, SSRIs therapeutic class and recommended the following to DHS by a unanimous vote:
  - ESCITALOPRAM SOLUTION (ORAL) to be moved from PREFERRED to the NONPREFERRED PDL
  - CITALOPRAM CAPSULE (ORAL), PAROXETINE SUSPENSION (ORAL) and SERTRALINE CAPSULE (ORAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Antiemetic/Antivertigo Agents therapeutic class and recommended the following to DHS by a unanimous vote:
  - TRANSDERM-SCOP (TRANSDERM) to be added to the PDL as PREFERRED
  - SCOPOLAMINE (TRANSDERM) to be added to the PDL as NONPREFERRED
  - VARUBI (ORAL) and ZUPLENZ (ORAL) to be removed from the PDL

- The committee discussed the Antifungals, Topical therapeutic class and recommended the following to DHS by a unanimous vote:
  - BENSAL HP (TOPICAL), CLOTRIMAZOLE SOLUTION OTC (TOPICAL), LULICONAZOLE (TOPICAL), MICONAZOLE NITRATE/ZINC OXIDE/PETROLATUM, (VUSION) (TOPICAL), NAFTAINE GEL (TOPICAL), SULCONAZOLE NITRATE CREAM (TOPICAL), SULCONAZOLE NITRATE SOLUTION (TOPICAL) and TOLNAFTATE SOLUTION OTC (TOPICAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Antimigraine Agents, Other therapeutic class and recommended the following to DHS by a unanimous vote:
  - ELYXYB SOLUTION (ORAL) AND TRUDHESA (NASAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Antimigraine Agents, triptans therapeutic class and recommended the following to DHS by a unanimous vote:
  - ZOLMITRIPTAN SPRAY (NASAL) to be added to the PDL as NONPREFERRED

- The committee discussed the Antiparasitics, Topical therapeutic class and recommended the following to DHS by a unanimous vote:
  - PIP BUTOXIDE/PYRETHRINS/PERMETHRIN KIT OTC (TOPICAL) to be moved from PREFERRED to the NONPREFERRED PDL

- The committee discussed the AntiParkinson’s Agents therapeutic class and recommended the following to DHS by a unanimous vote:
  - NEUPRO (TRANSDERM) to be added to the PDL as NONPREFERRED

- The committee discussed the Antipsychotics therapeutic class and recommended the following to DHS by a unanimous vote:
  - INVEGA HAFYERA (INTRAMUSC) to be added to the PDL as PREFERRED
  - LYBALVI (ORAL) to be added to the PDL as NONPREFERRED
• The committee discussed the Antivirals, Oral therapeutic class and recommended the following to DHS by a unanimous vote:
  o SITAVIG (BUCCAL) to be added to the PDL as NONPREFERRED

• The committee discussed the Beta Blockers therapeutic class and recommended the following to DHS by a unanimous vote:
  o NEBIVOLOL (ORAL) to be added to the PDL as NONPREFERRED

• The committee discussed the Bladder Relaxant Preparations class and recommended the following to DHS by a unanimous vote:
  o GEMTESA (ORAL) and MYRBETRIQ GRANULES (ORAL) to be added to the PDL as NONPREFERRED

• The committee discussed the Bronchodilators, Beta Agonist and recommended the following to DHS by a unanimous vote:
  o ARFORMOTEROL (INHALATION), FORMOTEROL (INHALATION) and LEVALBUTEROL HFA (INHALATION) to be added to the PDL as NONPREFERRED

• The committee discussed the Glucocorticoids, Inhaled class and recommended the following to DHS by a unanimous vote:
  o AIRDUO DIGIHALER (INHALATION) and ARMONAIR DIGIHALER (INHALATION) to be added to the PDL as NONPREFERRED

• The committee discussed the Hypoglycemics, Sulfonylureas class and recommended the following to DHS by a unanimous vote:
  o Removal of the class from the PDL.

**Consent Agenda Items**

• The committee discussed and recommended by unanimous vote that all classes in the Consent Agenda Items remain as presented with the exception of the Hypoglycemics, Incretin Mimetics/Enhancers class.

• The committee discussed and recommended to DHS by a unanimous vote that the Hypoglycemics, Incretin Mimetics/Enhancers class remain without any changes.

**Adjournment**

• The meeting was adjourned at approximately 8:02 p.m. Central Time.